AFRIN NO DRIP SEVERE CONGESTION OTC
Generic Name and Formulations:
Oxymetazoline HCl 0.05%; pump mist; contains menthol.
Merck & Co., Inc.
Indications for AFRIN NO DRIP SEVERE CONGESTION:
Adults and Children:
<6yrs: individualize. ≥6yrs: 2–3 sprays in each nostril not more than every 10–12 hours. Max 2 doses/day.
Use >3 days; may worsen nasal congestion.
Heart disease. Hypertension. Thyroid disease. Diabetes. Urinary retention. Enlarged prostate. Pregnancy. Nursing mothers.
Local effects (eg, burning, stinging, sneezing, increased nasal discharge).
Original nasal spray—30mL; No Drip Original, Severe Congestion, Extra Moisturizing, Sinus—15mL
Endocrinology Advisor Articles
- Efficacy and Safety of Alirocumab in Diabetes Mellitus
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Safety of DPP-IV Inhibitor, Cardiovascular Events After ACS in Type 2 Diabetes
- Effect of Fructose, Allulose on Postprandial Glucose Regulation in Type 2 Diabetes
- Sex Hormone Levels May Affect Postmenopausal Heart Disease Risk
- Diabetes Treatments
- Metformin May Decrease Colorectal Cancer Risk Among Males With Diabetes
- SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
- Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI
- FDA Clears Omnipod DASH System for Diabetes Management
- Menopausal Hormone Therapy Slows Cognitive Decline in Postmenopausal Women
- Does Maintenance of Certification Status Affect Patient Care?
- Emotional Hyper-Reactivity and Cardiometabolic Risk in Remitted Bipolar Disorder
- Reduced Mortality for Women Undergoing Assisted Reproduction Likely Due to "Healthy Patient Effect"
- Romosozumab Followed by Denosumab Effective for BMD Increase in Postmenopausal Women